PT1945665E - Terapêuticas à base de anticorpos com atividade adcc reforçada - Google Patents

Terapêuticas à base de anticorpos com atividade adcc reforçada Download PDF

Info

Publication number
PT1945665E
PT1945665E PT06846120T PT06846120T PT1945665E PT 1945665 E PT1945665 E PT 1945665E PT 06846120 T PT06846120 T PT 06846120T PT 06846120 T PT06846120 T PT 06846120T PT 1945665 E PT1945665 E PT 1945665E
Authority
PT
Portugal
Prior art keywords
cells
glycans
kifunensine
fusion protein
monoclonal antibody
Prior art date
Application number
PT06846120T
Other languages
English (en)
Inventor
John M Mcpherson
Tim Edmunds
Qun Zhou
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of PT1945665E publication Critical patent/PT1945665E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)

Description

DESCRIÇÃO
TERAPÊUTICAS À BASE DE ANTICORPOS COM ATIVIDADE ADCC
REFORÇADA

Claims (11)

  1. REIVINDICAÇÕES 1. Método de produzir um anticorpo monoclonal glicosilado ou proteína de fusão Fc tendo pelo menos 70% Man5_9 (GlcNAc)2 N-glicanos, e 10% ou menos de complexo N-glicanos, por razão molar, em relação a todos os N-glicanos, compreendendo: (a) proporcionar um anticorpo monoclonal produtor de células de mamífero ou uma proteína de fusão Fc produtora de células de mamíferos; (b) cultivar a célula na presença de kifunensine; e (c) recuperar o anticorpo glicosilado ou a proteína de fusão Fc.
  2. 2 . Método da reivindicação 1 , em que a kifunensine é utilizada numa concentração de 0,01 a 100 yg/ml para um período de pelo menos 12 horas.
  3. 3. Método da reivindicação 1 , em que a kifunensine é utilizada numa concentração de 0,01 a 50 pg/ml durante um período de pelo menos 12 horas.
  4. 4. Método da reivindicação 1 , em que a kifunensine é utilizada numa concentração de 0,01 a 20 yg/ml durante um período de pelo menos 12 horas.
  5. 5. Método da reivindicação 1, em que a kifunensine é usada numa concentração de 0,1 a 10 yg/ml para um período de pelo menos 12 horas.
  6. 6. Método da reivindicação 1, em que os ovários de hamster chinês CHO ou células de hibridoma são incubadas com 0,5 a 10 yg/ml de kifunensine ao longo de 10 dias. 1
  7. 7. Método da reivindicação 1, em que o anticorpo monoclonal ou proteina de fusão Fc tem, pelo menos, 90% de Man5_9 (GlcNAc)2 N-glicanos.
  8. 8. Método da reivindicação 1, em que o anticorpo monoclonal ou proteina de fusão Fc tem menos de 30% de Man5 (GlcNAc) 2 e/ou Man6(GlcNAc)2 N-glicanos por razão molar, em relação a todos os N-glicanos.
  9. 9. Método da reivindicação 1, em que o anticorpo monoclonal ou proteina de fusão Fc tem menos de 30% de N-glicanos fucosilados por razão molar, em relação a todos os N-glicanos.
  10. 10. Método de qualquer uma das reivindicações 1-9, em que as células são células de ovário de hamster chinês CHO, células de hibridoma de rato, células de mieloma, células humanas embrionárias de rim, células de rim de macaco, células epiteliais de carcinoma humano, células de fibrossarcoma humano, ou células de rim de hamster bebé.
  11. 11. Método da reivindicação 10, em que as células são células CHO. 2
PT06846120T 2005-10-21 2006-10-20 Terapêuticas à base de anticorpos com atividade adcc reforçada PT1945665E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72894705P 2005-10-21 2005-10-21

Publications (1)

Publication Number Publication Date
PT1945665E true PT1945665E (pt) 2012-04-20

Family

ID=37963422

Family Applications (1)

Application Number Title Priority Date Filing Date
PT06846120T PT1945665E (pt) 2005-10-21 2006-10-20 Terapêuticas à base de anticorpos com atividade adcc reforçada

Country Status (13)

Country Link
US (2) US7700321B2 (pt)
EP (1) EP1945665B1 (pt)
JP (1) JP5583908B2 (pt)
AR (1) AR058129A1 (pt)
AT (1) ATE536373T1 (pt)
CA (1) CA2626556C (pt)
CY (1) CY1112446T1 (pt)
DK (1) DK1945665T3 (pt)
ES (1) ES2376083T3 (pt)
PL (1) PL1945665T3 (pt)
PT (1) PT1945665E (pt)
SI (1) SI1945665T1 (pt)
WO (1) WO2007048122A2 (pt)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7749094B2 (en) * 2003-12-29 2010-07-06 Chen Yung Hsiang Golf club grip and manufacturing method thereof
US20080019905A9 (en) * 2005-02-18 2008-01-24 Strome Scott E Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection
EP1945666B1 (en) * 2005-10-21 2013-03-27 GTC Biotherapeutics, Inc. Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use
JP5583908B2 (ja) * 2005-10-21 2014-09-03 ジェンザイム・コーポレーション 増強されたａｄｃｃ活性を伴う抗体に基づく治療薬
GB0614947D0 (en) * 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy
AU2007308983B2 (en) * 2006-10-24 2012-12-06 Emergent Product Development Seattle, Llc A method for increasing antibody-dependent cytotoxicity with castanospermine
US7846434B2 (en) 2006-10-24 2010-12-07 Trubion Pharmaceuticals, Inc. Materials and methods for improved immunoglycoproteins
US20100291073A1 (en) 2007-05-14 2010-11-18 Medimmune, Llc Methods of reducing eosinophil levels
ES2462690T3 (es) 2008-02-05 2014-05-26 Bristol-Myers Squibb Company Anticuerpos alfa 5-beta 1 y sus usos
WO2009114641A1 (en) * 2008-03-11 2009-09-17 Genentech, Inc. Antibodies with enhanced adcc function
WO2009134389A2 (en) * 2008-05-01 2009-11-05 Gtc Biotherapeutics, Inc. An anti-cd137 antibody as an agent in the treatment of inflammatory conditions
CN102076865B (zh) 2008-05-02 2016-03-16 西雅图基因公司 用于制造核心岩藻糖基化降低的抗体和抗体衍生物的方法和组合物
EA030182B1 (ru) 2009-04-20 2018-07-31 Оксфорд Байотерепьютикс Лтд. Антитела, специфические для кадгерина-17
WO2011019620A1 (en) * 2009-08-10 2011-02-17 Genentech, Inc. Antibodies with enhanced adcc function
US20120231004A1 (en) 2009-10-13 2012-09-13 Oxford Biotherapeutic Ltd. Antibodies
EP2539370B1 (en) 2010-02-23 2019-05-15 Sanofi Anti-alpha2 integrin antibodies and their uses
HUE043370T2 (hu) 2010-08-05 2019-08-28 Seattle Genetics Inc Protein-fukoziláció in vivo gátlása fukóz analógok alkalmazásával
TWI560199B (en) 2010-08-31 2016-12-01 Sanofi Sa Peptide or peptide complex binding to α2 integrin and methods and uses involving the same
AR085302A1 (es) 2011-02-24 2013-09-18 Sanofi Sa Metodo de produccion de anticuerpos sialilados
DK2699598T3 (en) 2011-04-19 2019-04-23 Pfizer COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER
FR2976811A1 (fr) 2011-06-22 2012-12-28 Lfb Biotechnologies Utilisation d'un anticorps anti-cd20 a haute adcc pour le traitement de la maladie de waldenstrom
LT2726508T (lt) 2011-06-28 2017-09-11 Oxford Biotherapeutics Ltd Antikūnai prieš adp-ribozilciklazę 2
US20130149300A1 (en) * 2011-09-27 2013-06-13 Icon Genetics Gmbh MONOCLONAL ANTIBODIES WITH ALTERED AFFINITIES FOR HUMAN FCyRI, FCyRIIIa, AND C1q PROTEINS
ES2721882T3 (es) 2011-12-23 2019-08-06 Pfizer Regiones constantes de anticuerpo modificadas por ingeniería genética para conjugación específica de sitio y procedimientos y usos de las mismas
WO2014004549A2 (en) 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
BR112015001459B1 (pt) 2012-07-25 2023-02-14 Celldex Therapeutics, Inc Anticorpo isolado ou fragmento do mesmo, conjugado, usos dos mesmos, composição farmacêutica, polinucleotídeo, vetor, célula hospedeira, célula isolada, kit, método in vitro para inibir atividade da kit, método para produzir um anticorpo
WO2014031875A1 (en) 2012-08-23 2014-02-27 Seattle Genetics, Inc. Treatment of sickle cell disease and inflammatory conditions
JP6461808B2 (ja) 2012-12-17 2019-01-30 ラボラトワール フランセ ドゥ フラクションマン エ デ バイオテクノロジーズＬａｂｏｒａｔｏｉｒｅ Ｆｒａｎｃａｉｓ Ｄｕ Ｆｒａｃｔｉｏｎｎｅｍｅｎｔ Ｅｔ Ｄｅｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅｓ 炎症および細菌感染症処置におけるモノクローナル抗体の使用
BR112015019348A2 (pt) 2013-02-13 2017-08-22 Lab Francais Du Fractionnement Métodos para produção de proteína com glicosilação modificada e com sialilação aumentada, para aumentar a atividade de sialil transferase na glândula mamária e para produzir sialil transferase, proteína com glicosilação modificada ou proteína com sialilação aumentada, composição, sialil transferase, mamífero transgênico, e, célula epitelial mamária
EP2956480B1 (en) 2013-02-13 2019-09-04 Laboratoire Français du Fractionnement et des Biotechnologies Highly galactosylated anti-tnf-alpha antibodies and uses thereof
CN114717206A (zh) 2013-03-15 2022-07-08 Atyr 医药公司 组氨酰-trna合成酶-fc缀合物
KR102282691B1 (ko) 2013-09-30 2021-07-27 추가이 세이야쿠 가부시키가이샤 개변된 헬퍼 파지를 사용하여 항원 결합 분자를 제작하는 방법
FR3016633B1 (fr) 2014-01-17 2018-04-13 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Immunoglobuline anti-toxine du charbon
KR101660580B1 (ko) * 2014-04-02 2016-09-28 프레스티지 바이오파마 피티이. 엘티디. 항체의 당 함량 조절을 통한 항체의 제조 방법
TW201629215A (zh) * 2014-09-30 2016-08-16 拜耳保健有限責任公司 使用凝血酶之組成物及治療方法
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
WO2017058944A1 (en) 2015-09-29 2017-04-06 Amgen Inc. Asgr inhibitors
JP7011764B2 (ja) 2016-07-07 2022-01-27 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 抗体アジュバント複合体
CN110914298A (zh) * 2016-12-22 2020-03-24 赛诺菲 具有耗减活性的人源化cxcr3抗体及其使用方法
KR20190095942A (ko) * 2016-12-22 2019-08-16 사노피 백반증의 치료를 위한 항-인간 cxcr3 항체
TW201840585A (zh) * 2016-12-22 2018-11-16 法商賽諾菲公司 用於白斑病的治療的抗人cxcr3抗體
CN110536694A (zh) 2017-04-20 2019-12-03 Atyr 医药公司 用于治疗肺部炎症的组合物和方法
WO2018213064A1 (en) 2017-05-19 2018-11-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibody targeting tnfer2 for cancer immunotherapy
WO2020190725A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
WO2021127414A1 (en) 2019-12-20 2021-06-24 Bristol-Myers Squibb Company Use of fucosylation inhibitor for producing afucosylated antibody
EP4396236A1 (en) 2021-08-30 2024-07-10 Lassen Therapeutics 1, Inc. Anti-il-11r alpha antibodies
TW202430560A (zh) 2023-01-06 2024-08-01 美商拉森醫療公司 抗ｉｌ－１８ｂｐ抗體
TW202432591A (zh) 2023-01-06 2024-08-16 美商拉森醫療公司 抗ｉｌ－１８ｂｐ抗體
WO2024148240A1 (en) 2023-01-06 2024-07-11 Lassen Therapeutics 1, Inc. ANTI-IL-11Rα ANTIBODIES FOR TREATING THYROID EYE DISEASE

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
EP1071700B1 (en) * 1998-04-20 2010-02-17 GlycArt Biotechnology AG Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP2270150B2 (en) 1999-04-09 2019-08-07 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US6537785B1 (en) * 1999-09-14 2003-03-25 Genzyme Glycobiology Research Institute, Inc. Methods of treating lysosomal storage diseases
FR2807767B1 (fr) * 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
US7138262B1 (en) * 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
US20030124653A1 (en) * 2001-12-21 2003-07-03 Novazyme Pharmaceuticals, Inc. Method of producing glycoproteins having reduced complex carbohydrates in mammalian cells
JP5583908B2 (ja) 2005-10-21 2014-09-03 ジェンザイム・コーポレーション 増強されたａｄｃｃ活性を伴う抗体に基づく治療薬

Also Published As

Publication number Publication date
EP1945665A2 (en) 2008-07-23
US7700321B2 (en) 2010-04-20
ES2376083T3 (es) 2012-03-08
AR058129A1 (es) 2008-01-23
ATE536373T1 (de) 2011-12-15
DK1945665T3 (da) 2012-02-06
US20070092521A1 (en) 2007-04-26
PL1945665T3 (pl) 2012-02-29
WO2007048122A3 (en) 2007-09-20
US20100184145A1 (en) 2010-07-22
EP1945665B1 (en) 2011-12-07
CA2626556A1 (en) 2007-04-26
CY1112446T1 (el) 2015-12-09
JP2009512697A (ja) 2009-03-26
WO2007048122A2 (en) 2007-04-26
CA2626556C (en) 2016-05-10
US8071336B2 (en) 2011-12-06
SI1945665T1 (sl) 2012-03-30
JP5583908B2 (ja) 2014-09-03

Similar Documents

Publication Publication Date Title
PT1945665E (pt) Terapêuticas à base de anticorpos com atividade adcc reforçada
Chakraborty et al. Proinflammatory IgG Fc structures in patients with severe COVID-19
Harris et al. Refined structure of an intact IgG2a monoclonal antibody
Raju et al. Galactosylation variations in marketed therapeutic antibodies
BRPI0607490A2 (pt) anticorpos monoclonais antiinterferon alfa e métodos para uso
Maeda et al. Analysis of nonhuman N-glycans as the minor constituents in recombinant monoclonal antibody pharmaceuticals
Krishnamurthy et al. Glycopeptide analogues of PSGL-1 inhibit P-selectin in vitro and in vivo
Hayes et al. Fc gamma receptor glycosylation modulates the binding of IgG glycoforms: a requirement for stable antibody interactions
Lord et al. Sulfation of the bikunin chondroitin sulfate chain determines heavy chain· hyaluronan complex formation
CN102264765A (zh) 抗muc1抗体
CN110709103A (zh) 用于生物学样品中具有改善的性能的timp2的测定法
Marti Fernandez et al. The glycosylation site of myelin oligodendrocyte glycoprotein affects autoantibody recognition in a large proportion of patients
Tawara et al. A novel anti-CD44 variant 9 monoclonal antibody C44Mab-1 was developed for immunohistochemical analyses against colorectal cancers
Suzuki et al. Development of a novel anti-CD44 variant 4 monoclonal antibody C44Mab-108 for immunohistochemistry
Chandrasekaran et al. Mammalian sialyltransferase ST3Gal-II: its exchange sialylation catalytic properties allow labeling of sialyl residues in mucin-type sialylated glycoproteins and specific gangliosides
Suzuki et al. Anti-HER2 cancer-specific mAb, H2Mab-250-hG1, possesses higher complement-dependent cytotoxicity than trastuzumab
Giri et al. Structural requirements of anticoagulant protein S for its binding to the complement regulator C4b-binding protein
Chang et al. Fucosyl-agalactosyl IgG1 induces cholangiocarcinoma metastasis and early recurrence by activating tumor-associated macrophage
Argentova et al. Features, modulation and analysis of glycosylation patterns of therapeutic recombinant immunoglobulin A
CN103554256B (zh) 一种抗人糖化白蛋白单克隆抗体及其用途
Jankovic et al. Molecular forms and microheterogeneity of the oligosaccharide chains of pregnancy-associated CA125 antigen
Taniguchi From the γ-glutamyl cycle to the glycan cycle: a road with many turns and pleasant surprises
CN112041341A (zh) Ccl14的抗体和检测
Zeerleder et al. Sugar Matters: Improving In Vivo Clearance Rate of Highly Glycosylated Recombinant Plasma Proteins for Therapeutic Use
Sano et al. Survival signals of hepatic stellate cells in liver regeneration are regulated by glycosylation changes in rat vitronectin, especially decreased sialylation